Lipid nanoparticle technology for therapeutic gene regulation in the liver

Dominik Witzigmann, Jayesh A. Kulkarni, Jerry Leung, Sam Chen, Pieter R. Cullis (Corresponding author), Roy van der Meel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenAcademicpeer review

3 Citaten (Scopus)


Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of people around the globe and are a major public health burden. Most contemporary treatments offer limited relief as they generally aim to alleviate disease symptoms. Targeting the root cause of diseases originating in the liver by regulating malfunctioning genes with nucleic acid-based drugs s holds great promise as a therapeutic approach. However, employing nucleic acid therapeutics in vivo is challenging due to their unfavorable characteristics. Lipid nanoparticle (LNP) delivery technology is a revolutionary development that has enabled clinical translation of gene (editing) therapies. LNPs can deliver siRNA, mRNA, DNA, or gene-editing complexes, providing opportunities to treat hepatic diseases by silencing pathogenic genes, expressing therapeutic proteins, or correcting genetic defects. Here we discuss the state-of-the-art LNP technology for hepatic gene therapy including formulation design parameters, production methods, preclinical development and clinical translation.
Originele taal-2Engels
TijdschriftAdvanced Drug Delivery Reviews
StatusE-publicatie vóór gedrukte publicatie - 2 jul 2020

Vingerafdruk Duik in de onderzoeksthema's van 'Lipid nanoparticle technology for therapeutic gene regulation in the liver'. Samen vormen ze een unieke vingerafdruk.

Citeer dit